Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma-Reference-Cited by-同舟云学术

Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Published:2019-04-02 Issue:14 Volume:25 Page:4530-4541
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Wu Rui-Yan,Kong Peng-Fei,Xia Liang-Ping,Huang Yun,Li Zhi-Ling,Tang Yun-Yun,Chen Yu-Hong,Li Xuan,Senthilkumar Ravichandran,Zhang Hai-Liang,Sun Ting,Xu Xue-Lian,Yu Yan,Mai Jia,Peng Xiao-Dan,Yang Dong,Zhou Li-Huan,Feng Gong-Kan,Deng Rong,Zhu Xiao-Feng

Funder

National Key R&D Program of China

Natural Science Foundation of China

Science and Technology Project of Guangzhou

Fundamental Research Funds for the Central Universities of China

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

2. Inulin‐Based Nanoparticle Modulates Gut Microbiota and Immune Microenvironment for Improving Colorectal Cancer Therapy;Advanced Functional Materials;2024-09-02

3. PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed Patients;Cells;2024-08-28

4. Clinical predictive factors of the efficacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer;Clinical and Translational Oncology;2024-08-19

5. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302);BMC Cancer;2024-07-25